Citigroup’s Roivant Sciences ROIV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$748K Sell
27,000
-173,000
-87% -$4.44M ﹤0.01% 3303
2025
Q4
$4.34M Hold
200,000
﹤0.01% 2119
2025
Q3
$3.03M Buy
+200,000
New +$2.48M ﹤0.01% 2344
2024
Q2
Sell
-35,900
Closed -$378K 5746
2024
Q1
$378K Sell
35,900
-12,100
-25% -$130K ﹤0.01% 3723
2023
Q4
$539K Buy
+48,000
New +$468K ﹤0.01% 3353

Other funds holding ROIV

Citigroup's ROIV Position: Q1 2026 in Review

Citigroup reduced its Roivant Sciences (ROIV) stake by 10% in Q1 2026, selling an estimated $4.51M and leaving 1,536,110 shares worth $42.6M. The position accounts for 0.02% of the portfolio, ranked #699.

Citigroup first reported a position in ROIV in Q4 2021 and has held it in 18 quarters since. 439 funds tracked by Wall St. Rank hold ROIV as of Q1 2026.

  • Citigroup held 1,536,110 shares of Roivant Sciences worth $42.6M as of Q1 2026.
  • Citigroup sold 175,634 Roivant Sciences shares in Q1 2026, an estimated $4.51M.
  • Roivant Sciences made up 0.02% of Citigroup's portfolio in Q1 2026, its #699 holding.
  • Citigroup first reported a position in Roivant Sciences in Q4 2021 and has held it in 18 quarters since.
  • 439 funds tracked by Wall St. Rank held Roivant Sciences as of Q1 2026.

Based on Citigroup's 13F filing for Q1 2026, filed 11 May 2026.